Patient-reported problematic symptoms in an ALS treatment trial

References

• Simmons Z. Management Strategies for Patients With Amyotrophic Lateral Sclerosis From Diagnosis Through Death. Neurologist. 2005;11:257–70.
   PubMed Web of Science ®Google Scholar
• Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice Parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence based review). Neurology. American Academy of Neurology. 2009;73: 1218–26.
   PubMed Web of Science ®Google Scholar
• Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis. Multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence based review). Neurology. 2009;73:1227–33.
   PubMed Web of Science ®Google Scholar
• Miller RG, Brooks BR, Swain-Eng RJ, Basner RC, Carter GT, Casey P, et al. Quality improvement in neurology: amyotrophic lateral sclerosis quality measures. Report of the quality measurement and reporting subcommittee of the American Academy of Neurology. Neurology. 2013;81: 2136–40.
   PubMed Web of Science ®Google Scholar
• Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, van Damme P, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS): revised report of an EFNS task force. Eur J Neurol. 2012;19:360–75.
   PubMed Web of Science ®Google Scholar
• van den Berg JP, Kalmijn S, Lindeman E, Veldink JH, de Visser M, van der Graaff MM, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology. 2005;65:1264–7.
   PubMed Web of Science ®Google Scholar
• Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000. J Neurol Neurosurg Psychiatry. 2003;74: 1258–61.
   PubMed Web of Science ®Google Scholar
• Chiò A, Bottacchi E, Buffa C, Mutani R, Mora G. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry. 2006;77:948–50.
   PubMed Web of Science ®Google Scholar
• Rooney J, Byrne S, Heverin M, Tobin K, Dick A, Donaghy C, et al. A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland. J Neurol Neurosurg Psychiatry. 2015;86:496–501.
   PubMed Web of Science ®Google Scholar
• Aridegbe T, Kandler R, Walters SJ, Walsh T, Shaw PJ, McDermott CJ. The natural history of motor neuron disease: assessing the impact of specialist care. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:13–19.
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Lepore V, et al. ALS multidisciplinary clinic and survival. Results from a population based study in southern Italy. J Neurol. 2007;254:1107–12.
   PubMed Web of Science ®Google Scholar
• Stephens H, Young J, Felgoise S, Simmons Z. Multidisciplinary ALS Clinics in the USA: a Comparison of Those Who Attend and Those Who Do Not. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:196–201.
   PubMed Web of Science ®Google Scholar
• Simmons Z, Felgoise SH, Bremer BA, Walsh SM, Hufford DJ, Bromberg MB, et al. The ALSSQoL: balancing physical and non-physical factors in assessing quality of life in ALS. Neurology. 2006;67:1659–64.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:1083–91.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Fuller C, Hilt D, Thurmond B, Nakanishi A, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Schwartz CE, Sprangers MA. Methodological approaches for assessing response shift in longitudinal health-related quality-of-life research. Soc Sci Med. 1999;48:1531–48.
   PubMed Web of Science ®Google Scholar
• Carr AJ, Gibson B, Robinson PG. Measuring quality of life: is quality of life determined by expectations or experience? Br Med J. 2001;322:1240–3.
   PubMed Web of Science ®Google Scholar
• Yardley L, Dibb B. Assessing subjective change in chronic illness: an examination of response shift in health-related and goal-oriented subjective status. Psychol Health. 2007; 22:813–28.
   Web of Science ®Google Scholar
• Barclay R, Tate RB. Response shift recalibration and reprioritization in health related quality of life was identified prospectively in older males with and without stroke. J Clin Epidemiol. 2014;67:500–7.
   PubMed Web of Science ®Google Scholar
• McElhiney MC, Rabkin JG, Gordon PH, Goetz R, Mitsumoto H. Prevalence of fatigue and depression in ALS patients and change over time. J Neurol Neurosurg Psychiatry. 2009;80:1146–9.
   PubMed Web of Science ®Google Scholar
• Lo Coco D, La Bella V. Fatigue, sleep, and nocturnal complaints in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2012;19:760–3.
   PubMed Web of Science ®Google Scholar
• Gibbons CJ, Thornton EW, Young CA. The patient experience of fatigue in motor neuron disease. Front Psychol 2013;4:788. doi: 10.3389/fpsyg.2013.00788
   PubMed Web of Science ®Google Scholar
• Abraham A, Drory VE. Fatigue in motor neuron diseases. Neuromuscul Disord. 2012;22 (Suppl 3):S198–202.
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Gordon PH, McElhiney M, Rabkin R, Chew S, Mitsumoto H. Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle Nerve. 2009;39:297–303.
   PubMed Web of Science ®Google Scholar
• Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomized controlled trial. Lancet Neurol. 2006;5:140–7.
   PubMed Web of Science ®Google Scholar
• Butz M, Wollinsky KH, Wiedemuth-Catrinescu U, Sperfeld A, Winter S, Mehrkens HH, et al. Longitudinal effects of non-invasive positive-pressure ventilation in patients with amyotrophic lateral sclerosis. Am J Phys Med Rehabil. 2003;82:597–604.
   PubMed Web of Science ®Google Scholar
• Aboussouan LS, Khan SU, Banerjee M, Arroliga AC, Mitsumoto H. Objective measures of the efficacy of non-invasive positive-pressure ventilation in amyotrophic lateral sclerosis. Muscle Nerve. 2001;24:403–9.
   PubMed Web of Science ®Google Scholar
• Jackson CE, Rosenfeld J, Moore DH, Bryan WW, Barohn RJ, Wrench M, et al. A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients. J Neurol Sci. 2001;191:75–8.
   PubMed Web of Science ®Google Scholar
• Lyall RA, Donaldson N, Fleming T, Wood C, Newsom-Davis I, Polkey MI, et al. A prospective study of quality of life in ALS patients treated with non-invasive ventilation. Neurology. 2001;57:153–6.
   PubMed Web of Science ®Google Scholar
• Bourke SC, Bullock RE, Williams TL, Shaw PJ, Gibson GJ. Non-invasive ventilation in ALS: indications and effect on quality of life. Neurology. 2003;61:171–7.
   PubMed Web of Science ®Google Scholar
• Ganzini L, Johnston WS, Hoffman WF. Correlates of suffering in amyotrophic lateral sclerosis. Neurology. 1999;52:1434–40.
   PubMed Web of Science ®Google Scholar
• Chiò A, Canosa A, Gallo S, Moglia C, Ilardi A, Cammarosano S, et al. Pain in amyotrophic lateral sclerosis: a population based controlled study. Eur J Neurol. 2012;19:551–5.
   PubMed Web of Science ®Google Scholar
• Wallace VCJ, Ellis CM, Burman R, Knights C, Shaw CE, Al-Chalabi A. The evaluation of pain in amyotrophic lateral sclerosis: a case controlled observational study. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15:520–7.
   PubMed Web of Science ®Google Scholar
• Hanisch F, Skudlarek A, Berndt J, Kornhuber ME. Characteristics of pain in amyotrophic lateral sclerosis. Brain Behav. 2015;5:e00296. doi: 10.1002/brb3.296.
   PubMed Web of Science ®Google Scholar
• Handy CR, Krudy C, Boulis N, Federici T. Pain in amyotrophic lateral sclerosis: a neglected aspect ofdisease. Neurol Res Int. 2011;2011:403808. doi: 10.1155/2011/403808.
   PubMedGoogle Scholar
• Simmons Z. Rehabilitation of motor neuron disease. In: Barnes M, Good D, eds. Neurorehabilitation. Handbook of Clinical Neurology (Michael Aminoff, series ed). Amsterdam: Elsevier; 2013. pp 483–98.
   Google Scholar
• Weiss M, Simmons Z, Atassi N, Graves M, Parziale N, Salameh J, et al. A Phase II Study of Mexiletine in Sporadic Amyotrophic Lateral Sclerosis. Neurology. 2015;84: S50.004.
   Web of Science ®Google Scholar
• Nübling GS, Mie E, Bauer RM, Hensler M, Lorenzl S, Hapfelmeier A, et al. Increased prevalence of bladder and intestinal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15:174–9.
   PubMed Web of Science ®Google Scholar
• Tomik B, Guiloff RJ. Dysarthria in amyotrophic lateral sclerosis: a review. Amyotroph Lateral Scler. 2010; 11:4–15.
   PubMed Web of Science ®Google Scholar
• Körner S, Sieniawski M, Siniawski M, Kollewe K, Rath KJ, Krampfl K, et al. Speech therapy and communication device: impact on quality of life and mood in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:20–5.
   PubMed Web of Science ®Google Scholar
• da Costa Franceschini A, Mourão LF. Dysarthria and dysphagia in amyotrophic lateral sclerosis with spinal onset: a study of quality of life related to swallowing. NeuroRehabilitation. 2015;36:127–34.
   PubMed Web of Science ®Google Scholar
• Londral A, Pinto A, Pinto S, Azevedo L, de Carvalho M. Quality of life in ALS patients and caregivers: impact of assistive communication from early stages. Muscle Nerve. 2015; Mar 25. doi: 10.1002/mus.24659.
   PubMed Web of Science ®Google Scholar
• Kasarskis EJ, Mendiondo MS, Wells S, Malguizo MS, Thompson M, Healey M, et al. The ALS Nutrition/NIPPV Study: design, feasibility, and initial results. Amyotroph Lateral Scler. 2011;12:17–25.
   PubMed Web of Science ®Google Scholar
• Greenwood DI. Nutrition management of amyotrophic lateral sclerosis. Nutr Clin Pract. 2013;28:392–9.
   PubMed Web of Science ®Google Scholar
• Kasarskis EJ, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, et al. Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis. Am J Clin Nutr. 2014;99:792–803.
   PubMed Web of Science ®Google Scholar
• Bradley WG, Anderson F, Bromberg M, Gutmann L, Harati Y, Ross M, et al. Current management of ALS: comparison of the ALS CARE Database and the AAN Practice Parameter. Neurology. 2001;57:500–4.
   PubMed Web of Science ®Google Scholar
• Young CA, Ellis C, Johnson J, Sathasivam S, Pih N. Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane database Syst Rev 2011;CD006981. DOI: 0.1002/14651858.CD006981.pub2.
   Web of Science ®Google Scholar
• Stokholm MG, Bisgård C, Vilholm OJ. Safety and administration of treatment with botulinum neurotoxin for sialorrhoea in ALS patients: review of the literature and a proposal for tailored treatment. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14:516–20.
   PubMed Web of Science ®Google Scholar
• Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2000;69:121–3.
   PubMed Web of Science ®Google Scholar
• Verma A, Steele J. Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve. 2006;34:235–7.
   PubMed Web of Science ®Google Scholar
• Scott KR, Kothari MJ, Venkatesh YS, Murphy T, Simmons Z. Parotid gland injections of botulinum toxin a are effective in treating sialorrhea in amyotrophic lateral sclerosis. J Clin Neuromuscul Dis. 2005;7:62–5.
   PubMedGoogle Scholar
• Neppelberg E, Haugen DF, Thorsen L, Tysnes O-B. Radiotherapy reduces sialorrhea in amyotrophic lateral sclerosis. Eur J Neurol. 2007;14:1373–7.
   PubMed Web of Science ®Google Scholar
• Kasarskis EJ, Hodskins J, St. Clair WH. Unilateral parotid electron beam radiotherapy as palliative treatment for sialorrhea in amyotrophic lateral sclerosis. J Neurol Sci. 2011;308:155–7.
   PubMed Web of Science ®Google Scholar
• Gauthier A, Vignola A, Calvo A, Cavallo E, Moglia C, Sellitti L, et al. A longitudinal study on quality of life and depression in ALS patient-caregiver couples. Neurology. 2007;68:923–6.
   PubMed Web of Science ®Google Scholar
• Cupp J, Simmons Z, Berg A, Felgoise SH, Walsh SM, Stephens HE. Psychological health in patients with ALS is maintained as physical function declines. Amyotroph Lateral Scler. 2011;12:290–6.
   PubMed Web of Science ®Google Scholar